Posted from: Friday, November 10, 2017 - 06:02 PM - Present

Fiasp Approved for Diabetes

September 29, 2017 – The U.S. FDA has approved Fiasp® (insulin aspart injection) 100 units/mL, manufactured by Novo Nordisk, for the management of blood sugar levels in adults who have either type 1 or type 2 diabetes. Fiasp is a new form of rapid-acting insulin, designed to be absorbed more quickly and effectively once injected than other insulins. The improved absorption rate is achieved by incorporating niacinamide (vitamin B3) as part of the product’s formulation.

A mealtime insulin, Fiasp should be taken either before a meal or within 20 minutes of beginning to eat. The product will be available in 10mL multi-dose vials, as well as pre-filled FlexTouch® pens. Although a release date has not yet been announced, Novo Nordisk has indicated that Fiasp will be offered at the same price as NovoLog® (insulin aspart). The company plans to offer a savings card program for eligible patients to reduce copays, as well as a patient assistance program for individuals who meet certain criteria. 


Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by U.S. mail or by fax.

Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability. 

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.


Last Updated Friday, October 18, 2019 - 12:47 PM.